Research indicates that progression-free survival and duration of response to Nivolumab (an anti-PD-1 antibody), Ipilimumab (an anti-CTLA-4 antibody), or Pembrolizumab (another anti-PD-1 antibody) are greater in individuals with high tumor mutational burdens (TMBs) compared to those with lower mutational burdens [48]. This evidence concerns the gene PDCD1 and neoplasm.